55 North Private Wealth LLC Invests $387,000 in Astrazeneca Plc $AZN

55 North Private Wealth LLC purchased a new position in shares of Astrazeneca Plc (NYSE:AZN) in the 4th quarter, according to the company in its most recent filing with the SEC. The institutional investor purchased 4,210 shares of the company’s stock, valued at approximately $387,000.

Several other institutional investors and hedge funds also recently made changes to their positions in the company. Triumph Capital Management bought a new position in Astrazeneca in the 3rd quarter worth about $25,000. Bangor Savings Bank boosted its stake in Astrazeneca by 102.7% in the 4th quarter. Bangor Savings Bank now owns 304 shares of the company’s stock worth $28,000 after purchasing an additional 154 shares during the period. Eagle Bay Advisors LLC bought a new position in Astrazeneca in the 4th quarter worth about $30,000. Rakuten Investment Management Inc. bought a new position in Astrazeneca in the 3rd quarter worth about $31,000. Finally, YANKCOM Partnership bought a new position in Astrazeneca in the 4th quarter worth about $31,000. Institutional investors own 20.35% of the company’s stock.

Astrazeneca Price Performance

Shares of NYSE AZN opened at $205.03 on Monday. The stock has a market cap of $317.98 billion, a P/E ratio of 35.32, a PEG ratio of 1.54 and a beta of 0.35. The company has a debt-to-equity ratio of 0.51, a quick ratio of 0.72 and a current ratio of 0.94. Astrazeneca Plc has a 1-year low of $132.32 and a 1-year high of $212.71.

Astrazeneca Announces Dividend

The business also recently declared a dividend, which was paid on Monday, March 23rd. Shareholders of record on Friday, February 20th were paid a $1.595 dividend. This represents a yield of 156.0%. The ex-dividend date of this dividend was Friday, February 20th. Astrazeneca’s payout ratio is 74.83%.

Wall Street Analysts Forecast Growth

A number of brokerages have recently issued reports on AZN. Barclays reiterated an “overweight” rating on shares of Astrazeneca in a research report on Tuesday, January 6th. Morgan Stanley reiterated an “overweight” rating on shares of Astrazeneca in a research report on Wednesday, April 8th. TD Cowen reiterated a “buy” rating on shares of Astrazeneca in a research report on Wednesday, March 18th. Weiss Ratings began coverage on Astrazeneca in a research report on Wednesday, March 11th. They set a “buy (b)” rating for the company. Finally, Deutsche Bank Aktiengesellschaft reiterated a “sell” rating on shares of Astrazeneca in a research report on Friday, February 6th. Eight equities research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat, Astrazeneca presently has a consensus rating of “Moderate Buy” and an average price target of $102.67.

About Astrazeneca

AstraZeneca plc is a global biopharmaceutical company headquartered in Cambridge, England. Formed through the 1999 merger of Sweden’s Astra AB and the UK’s Zeneca Group, the company researches, develops, manufactures and commercializes prescription medicines across a range of therapeutic areas. AstraZeneca positions itself as R&D-driven, investing in discovery science, clinical development and regulatory processes to bring new therapies to market.

The company’s commercial portfolio and late-stage pipeline emphasize oncology, cardiovascular, renal and metabolic (CVRM) diseases, and respiratory and immunology.